Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study - Pasi, K. John; Fischer, Kathelijn; Ragni, Margaret; Kulkarni, Roshni; Ozelo, Margareth C.; Mahlangu, Johnny; Shapiro, Amy; P’Ng, Stephanie; Chambost, Hervé; Nolan, Beatrice; Bennett, Carolyn; Matsushita, Tadashi; et al. (Haemophilia : the official journal of the World Federation of Hemophilia, 2020)
Keywords: bleed rate; Coagulation factors; extended half‐life; factor IX; Factor IX deficiency; Fc receptors; Fusion protein; haemophilia B; Hematology; Hemophilia; Human health and pathology; individualized prophylaxis; Life Sciences; Pediatrics; perioperative haemostasis; Prophylaxis; rFIXFc; Safety; factor IX; haemophilia B; bleed rate; rFIXFc; extended half-life; perioperative haemostasis; individualized prophylaxis